CorMedix (NASDAQ:CRMD) to Repurchase $75.00 million in Outstanding Shares

CorMedix (NASDAQ:CRMD - Get Free Report) announced that its board has authorized a stock buyback plan on Monday, February 2nd, RTT News reports. The company plans to repurchase $75.00 million in shares. This repurchase authorization permits the company to repurchase up to 12.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board believes its shares are undervalued.CorMedix Trading Up 5.3%High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026NASDAQ CRMD traded up $0.41 during trading hours on Monday, hitting $8.17. 3,483,801 shares of the company's stock were exchanged, compared to its average volume of 4,083,835. CorMedix has a 12-month low of $5.60 and a 12-month high of $17.43. The business's 50 day moving average is $9.90 and its 200-day moving average is $11.07. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.73 and a current ratio of 1.94. The firm has a market capitalization of $643.71 million, a P/E ratio of 3.97 and a beta of 1.39. CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.78. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The business had revenue of $104.28 million during the quarter, compared to analysts' expectations of $65.63 million. During the same quarter in the previous year, the business earned ($0.05) EPS. The company's revenue for the quarter was up 810.2% on a year-over-year basis. As a group, analysts anticipate that CorMedix will post -0.32 EPS for the current fiscal year. Analyst Ratings ChangesWhy CorMedix Could be the Biopharma Name to Watch Early in 2026Several brokerages have recently weighed in on CRMD. Zacks Research cut CorMedix from a "strong-buy" rating to a "hold" rating in a report on Monday, January 12th. Weiss Ratings restated a "hold (c)" rating on shares of CorMedix in a research report on Wednesday, January 21st. D. Boral Capital reaffirmed a "buy" rating and set a $14.00 price target on shares of CorMedix in a research note on Thursday, January 8th. D Boral Capital upgraded shares of CorMedix from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 20th. Finally, HC Wainwright decreased their price objective on shares of CorMedix from $18.00 to $13.00 and set a "buy" rating on the stock in a report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $15.86.Check Out Our Latest Report on CRMDInsiders Place Their BetsMarketBeat’s Top 5 Rated Small-Cap StocksIn other CorMedix news, Director Steven W. Lefkowitz sold 40,000 shares of CorMedix stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the sale, the director directly owned 80,498 shares in the company, valued at $956,316.24. The trade was a 33.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph Todisco sold 30,000 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. Following the transaction, the chief executive officer owned 509,496 shares of the company's stock, valued at approximately $6,113,952. This trade represents a 5.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 90,000 shares of company stock worth $1,095,200 in the last quarter. 3.10% of the stock is owned by corporate insiders. CorMedix Company Profile Get Free Report)CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company's lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers. In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.Further ReadingFive stocks we like better than CorMedix[No Brainer Gold Play]: “Show me a better investment.”New gold price targetForget AI, This Will Be the Next Big Tech BreakthroughEnd of America UpdateThe gold chart Wall Street is terrified of…This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CorMedix Right Now?Before you consider CorMedix, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.While CorMedix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here